Inside Intestinal Disease
Sheena Cruickshank explains how examining gut mucus microbiota can lead to earlier diagnosis – or even prediction – of inflammatory bowel disease
Sheena Cruickshank |
Inflammatory bowel diseases (IBD) are relapsing and remitting chronic conditions of the gut that have a major impact on patients’ quality of life. Current therapeutic approaches aim to reduce symptoms – but their effectiveness varies, and patients may develop tolerances to the drugs. As such, it’s really important to have ways of assessing disease activity to better manage patients. Identifying microbial alterations associated with IBD could provide a diagnostic tool that enables us to spot disease earlier and minimize damage. It also contributes to better understanding of the underlying mechanisms associated with disease pathogenesis, allowing the design of improved therapeutic strategies.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts